Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder

Neuropsychopharmacology

Volumn 29, Issue 7, 2004, Pages 1353-1362

  Clinton, Sarah M ^a,b   Meadow Woodruff, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Glutamate; Mediodorsal nucleus; NF L; PSD95; SAP102

Indexed keywords

CELL ENZYME; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN NF; PROTEIN SAP 102; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IN SITU HYBRIDIZATION; MALE; MOOD DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; THALAMUS;

ADULT; AGED; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SPACE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; NEUROPEPTIDES; NUCLEAR PROTEINS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; THALAMUS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 2942666210     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300451     Document Type: Article

References (70)

1. Andreasen NC (1997). The role of the thalamus in schizophrenia. Can J Psychiatry 42: 27-33.
2. Andreasen NC, Arndt S, Swayze II V, Cizadlo T, Flaum M, O'Leary D et al (1994). Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266: 294-298.
3. Audinat E, Lambolez B, Rossier J, Crepel F (1994). Activity-dependent regulation of N-methyl-D-aspartate receptor subunit expression in rat cerebellar granule cells. Eur J Neurosci 6: 1792-1800.
4. Bogousslavsky J, Ferrazzini M, Regli F, Assal G, Tanabe H, Delaloye-Bischof A (1988). Manic delirium and frontal-like syndrome with paramedian infarction of the right thalamus. J Neurol Neurosurg Psychiatry 51: 116-119.
5. Boyer PA, Skolnick P, Fossom LH (1998). Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci 10: 219-233.
6. Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A et al (1996). PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 153: 191-199.
7. Buchsbaum M, Someya T, Wu J, Tang CY, Bunney WE (1997). Neuroimaging of bipolar illness with positron emission tomography and magnetic resonance imaging. Psychiatric Ann 27: 489-495.
8. Byne W, Buchsbaum MS, Kemether E, Hazlett EA, Shinwari A, Mitropoulou V et al (2001). Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch Gen Psychiatry 58: 133-140.
9. Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y et al (2002). Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 415: 793-798.
10. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V et al (2002). Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 4: 129-136.
11. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH (2003). Altered expression of NMDA receptor-associated post-synaptic density proteins in the thalamus in schizophrenia. Am J Psychiatry 160: 1100-1109.
12. Clinton SM, Meador-Woodruff JH (2002). Nucleus-specific expression of NMDA receptor-associated postsynaptic density proteins in primate thalamus. Thalamus Relat Systems 1: 303-316.
13. Clinton SM, Meador-Woodruff JH (2003). Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophrenia Res (in press).
14. Cohen B, Wan W (1996). The thalamus as a site of action of antipsychotic drugs. Am J Psychiatry 153: 104-106.
15. Coyle JT (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 3: 241-253.
16. Cummings JL, Mendez MF (1984). Secondary mania with focal cerebrovascular lesions. Am J Psychiatry 141: 1084-1087.
17. Das S, Sasaki YF, Rothe T, Premkumar LS, Takasu M, Crandall JE et al (1998). Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 393: 377-381.
18. Dasari M, Friedman L, Jesberger J, Stuve TA, Findling RL, Swales TP et al (1999). A magnetic resonance imaging study of thalamic area in adolescent patients with either schizophrenia or bipolar disorder as compared to healthy controls. Psychiatry Res 91: 155-162.
19. Deicken RF, Eliaz Y, Feiwell R, Schuff N (2001). Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. Psychiatry Res 106: 35-45.
20. Denicoff KD, Ali SO, Mirsky AF, Smith-Jackson EE, Leverich GS, Duncan CC et al (1999). Relationship between prior course of illness and neuropsychological functioning in patients with bipolar disorder. J Affective Disord 56: 67-73.
21. Deutch A, Ongur D, Duman R (1995). Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel antipsychotic drug action. Neuroscience 66: 337-346.
22. Dewan MJ, Haldipur CV, Lane EE, Ispahani A, Boucher MF, Major LF (1988). Bipolar affective disorder. I. Comprehensive quantitative computed tomography. Acta Psychiatr Scand 77: 670-676.
23. Dolan RJ, Poynton AM, Bridges PK, Trimble MR (1990). Altered magnetic resonance white-matter T1 values in patients with affective disorder. Br J Psychiatry 157: 107-110.
24. Dracheva S, Marras SAE, Elhakem SL, Kramer FR, Davis KL, Haroutunian V (2001). N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158: 1400-1410.
25. Drevets WC, Spitznagel E, Raichle ME (1995). Functional anatomical differences between major depressive subtypes. J Cereb Blood Flow Metab 15: S93.
26. Dupont RM, Jernigan TL, Heindel W, Butters N, Shafer K, Wilson T et al (1995). Magnetic resonance imaging and mood disorders. Localization of white matter and other subcortical abnormalities. Arch Gen Psychiatry 52: 747-755.
27. Ehlers M, Fung E, O'Brien R, Huganir R (1998). Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J Neurosci 18: 720-730.
28. Ehlers MD, Tingley WG, Huganir RL (1995). Regulated subcellular distribution of the NR1 subunit of the NMDA receptor. Science 269: 1734-1737.
29. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157: 1141-1149.
30. Gilbert AR, Rosenberg DR, Harenski K, Spencer S, Sweeney JA, Keshavan MS (2001). Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry 158: 618-624.
31. Goff D, Berman I, Posever T, Herz L, Leahy L, Lynch G (1999). A preliminary dose escalation trial of CX516 (Ampakine) added to clozapine in schizophrenia. Schizophrenia Res 36: 280.
32. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
33. Goff DC, Tsai G, Manoach DS, Coyle JT (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152: 1213-1215.
34. Goff DC, Wine L (1997). Glutamate in schizophrenia: clinical and research implications. Schizophrenia Res 27: 157-168.
35. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002). Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80: 589-597.
36. Hazlett EA, Buchsbaum MS, Byne W, Wei TC, Spiegel-Cohen J, Geneve C et al (1999). Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am J Psychiatry 156: 1190-1199.
37. Holcomb H, Cascella N, Thaker G, Medoff D, Dannals R, Tamminga C (1996). Funcitonal sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 153: 41-49.
38. Hollmann M, Heinemann S (1994). Cloned glutamate receptors. Annu Rev Neurosci 17: 31-108.
39. Ibrahim H, Healy D, Hogg AJ, Meador-Woodruff J (2000a). Nucleus-specific expression of ionotropic glutamate receptor subunit mRNAs and binding sites in primate thalamus. Mol Brain Res 79: 1-17.
40. Ibrahim HM, Hogg AJ, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH (2000b). Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 157: 1811-1823.
41. Javitt D, Zylberman I, Zukin S, Heresco-Levy U, Lindenmayer J (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234-1336.
42. Jones EG (1997). Cortical development and thalamic pathology in schizophrenia. Schizophrenia Bull 23: 483-501.
43. Jones EG (1998). The thalamus of primates. In: Bloom FE, Bjorklund A, Hokfelt T (eds). The Primate Nervous System, Part II, Vol 14, New York: Elsevier. pp 1-246.
44. Jones EG, Tighilet B, Tran BV, Huntsman MM (1998). Nucleus-and cell-specific expression of NMDA and non-NMDA receptor subunits in monkey thalamus. J Comp Neurol 397: 371-393.
45. Krishnan KR, Doraiswamy PM, Figiel GS, Husain MM, Shah SA, Na C et al (1991). Hippocampal abnormalities in depression. J Neuropsychiatry Clin Neurosci 3: 387-391.
46. Krishnan KR, McDonald WM, Doraiswamy PM, Tupler LA, Husain M, Boyko OB et al (1993). Neuroanatomical substrates of depression in the elderly. Eur Arch Psychiatry Clin Neurosci 243: 41-46.
47. Lahti A, Holcomb H, Medoff D, Tamminga C (1995). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6: 869-872.
48. Mialet JP, Pope HG, Yurgelun-Todd D (1996). Impaired attention in depressive states: a non-specific deficit? Psychol Med 26: 1009-1020.
49. Miller JA (1991). The calibration of 35S or 32P with 14C-labeled brain paste or 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm. Neurosci Lett 121: 211-214.
50. Oke AF, Adams RN (1987). Elevated thalamic dopamine: possible link to sensory dysfunctions in schizophrenia. Schizophrenia Bull 13: 589-604.
51. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatric Res 33: 523-533.
52. Pakkenberg B (1990). Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 47: 1023-1028.
53. Popken GJ, Bunney Jr WE, Potkin SG, Jones EG (2000). Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc Natl Acad Sci USA 97: 9276-9280.
54. Rahman S, Li PP, Young LT, Kofman O, Kish SJ, Warsh JJ (1997). Reduced [3H] cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem 68: 297-304.
55. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH (2000). Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 47: 22-28.
56. Sax KW, Strakowski SM, Zimmerman ME, DelBello MP, Keck Jr PE, Hawkins JM (1999). Frontosubcortical neuroanatomy and the continuous performance test in mania. Am J Psychiatry 156: 139-141.
57. Shaw G (1991). Neurofilament proteins. In: Burgoyne RD (ed). The Neuronal Cytoskeleton. New York: Wiley-Liss Inc. pp 621-635.
58. Sheng M (2001). The postsynaptic NMDA-receptor - PSD-95 signaling complex in excitatory synapses of the brain. J Cell Sci 114: 1251.
59. Sheng M, Pak D (2000). Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Annu Rev Physiol 62: 755-778.
60. Shenolikar S (1994). Protein serine/threonine phosphatases - new avenues for cell regulation. Ann Rev Cell Biol 10: 55-86.
61. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S et al (1995). A functional neuroanatomy of hallucinations in schizophrenia. Nature 378: 176-179.
62. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH (2001a). Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 158: 1393-1399.
63. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH (2001b). Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport 12: 2885-2887.
64. Soares JC, Mann JJ (1997). The anatomy of mood disorders - review of structural neuroimaging studies. Biol Psychiatry 41: 86-106.
65. Strakowski SM, DelBello MP, Sax KW, Zimmerman ME, Shear PK, Hawkins JM et al (1999). Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch Gen Psychiatry 56: 254-260.
66. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglass AW, Stoll AL (1993). Structural brain abnormalities in first-episode mania. Biol Psychiatry 33: 602-609.
67. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN et al (1992). Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49: 522-530.
68. Terry-Lorenzo R, Inoue M, Connor J, Haystead T, Armbruster B, Gupta R et al (2000). Neurofilament-L is a protein phosphatase-1-binding protein associated with neuronal plasma membrane and post-synaptic density. J Biol Chem 275: 2139-2446.
69. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH (2000). The Stanley foundation brain collection and neuropathology consortium. Schizophrenia Res 44: 151-155.
70. Ulas J, Nguyen L, Cotman CW (1993). Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport 4: 1049-1051.